Effect of Zinc Gluconate Supplementation on C-Reactive Protein and Malondialdehyde in Patients with Behcet's Disease: A Double-Blind Randomized Controlled Clinical Trial

Background:  Behçet's disease (BD) with autoimmune and auto-inflammatory nature is more prevalent in Silk Road countries. The current study aimed to investigate the effect of zinc gluconate supplementation on C-reactive protein (CRP) and malondialdehyde (MDA) levels in BD patients. Methods: This randomized controlled clinical trial was conducted on ۵۰ Iranian BD patients. Participants were randomly assigned into either placebo or zinc gluconate (۳۰ mg/day) groups for ۱۲ weeks. Before and after the intervention, serum MDA and CRP levels were measured. Results: Zinc supplementation led to a significant increase in serum zinc levels compared to the placebo group (P<۰.۰۵). There was no significant difference in MDA serum levels between the groups after adjusting for the baseline values and confounding factors (P>۰.۰۵). Zinc supplementation led to a significant improvement in CRP serum levels compared to the placebo group following adjustment for the effect of baseline values and confounding factors (P=۰.۰۱۲ and ۰.۰۴, respectively). Conclusion: Zinc supplementation in an elemental dose of ۳۰ mg per day has an anti-inflammatory effect in BD patients by reducing CRP levels. The beneficial effect of zinc on lipid peroxidation in BD patients was not shown in the study.

کلیدواژه ها:

Malondialdehyde ، Zinc ، CRP ، Behcet disease.